• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.
By STEPHEN GUILFOYLE
Dec 14, 2020 | 10:24 AM EST
Stocks quotes in this article: PFE, BNTX, MRNA, JNJ, AZN, ALXN, ABBV, MRK, BMY

Vaccine-Driven Morning

Equity index futures are trading well above fair value on Monday morning. Amid all of the death and illness that the Covid-19 pandemic has forced upon the human race, optimism is renewed as the first shipments of the recently authorized (for emergency use) Pfizer (PFE) / BioNTech (BNTX) vaccine makes its way around the nation, and the globe. Supplies are extremely limited and those in need will be prioritized. That said, with a bit of luck, another developer, U.S. biotech Moderna (MRNA) kneels in the on-deck circle, hopefully ready to add to available supplies of early vaccines as soon as next week.

Others are close. One would be Johnson & Johnson (JNJ) , working on a one-dose vaccine that scuttlebutt has it, could produce serious data as early as next month. Then there is AstraZeneca (AZN)  -- and it is difficult to assess just how excited we can get over the viral vector-based vaccine derived from a coronavirus that infects chimpanzees. There have been questions about the vaccine's efficacy, but even worst case, the number you hear is 70% on average.

That's not the 95% number that the messenger RNA vaccines seem to be able to boast of, but still far better than the original goal of 50% efficacy that planet earth seemed ready to accept a few months back -- if they could get it. This vaccine also had clinical studies halted for a while as a volunteer in the UK had developed a negative neurological issue that was determined to not be directly related to the vaccine.

I will tell you, as a Covid survivor, lasting neurological side effects are part of Covid, so this is a real concern for myself and many other survivors as we weigh the safety of these vaccines. Nobody knows if it is safe for those who have suffered the overactive immune response. Let's think about this stock, AstraZeneca, as that name is top of the news this morning for reasons other than coronavirus vaccines.

Acquisition

Over the weekend, AstraZeneca announced that the firm has entered into an agreement to acquire Alexion (ALXN) , a firm specializing in researching potential treatment for rare and ultra-rare diseases. Why would AstraZeneca do this? Growth. When growth slows and you can buy it, you do. AZN is trading lower this morning, both here and abroad, as the firm will pay a hefty premium.

On Friday night, ALXN closed at $120.98. I see the shares trading close to $158 prior to Monday's opening bell. Under the terms agreed to, Alexion shareholders will receive $60 in cash and 2.1243 shares of AZN, which is an ADS, in exchange for each one share of AXLN.

A little backstory? AstraZeneca reported a disappointing quarter back on November 5. The firm swung and missed on forecasts for both sales and profitability. Year-over-year revenue growth had slowed from 16% to 8% to 2.7%, sequentially. They needed to get out there and buy something without much overlap.

Alexion currently has a pipeline of eleven molecules across more than twenty clinical development programs working on a broad array of rare diseases. Current projections for the global market for rare disease treatment indicate it should become a double-digit growth business. I have read that only a rough 5% of over 7K rare diseases have FDA-approved therapeutics.

The short of it is this. AZN sales growth has been slowing rapidly. ALXN has seen sales growth remain steady in the 20% plus range for quarter after quarter, and focuses on a field of study that should grow, itself. Hence, the approximately 45% premium (based on Friday's closing prices, not pre-opening last sales). Alexion shareholders will end up controlling about 15% of the combined company.

Investors will note that AstraZeneca did enter into a bridge financing facility on Friday ahead of announcing the deal, but at least given how little overlap there is between the two, one would think that there should not be a lot in the way of regulatory issue that slow or prevent the deal from closing. The deal should close by Q3 2021, and should provide $500 million in recurring run rate, pre-tax synergies per year by the end of year three.

My Thoughts

As readers well know, I have not been shy about investing in big pharma or specific biotechs. I remain long Pfizer, Moderna, Johnson & Johnson, AbbVie (ABBV) , and Merck (MRK) . I have my eyes on Bristol-Myers Squibb (BMY) . To tell you the truth, I like them all more than AZN. Based on forward P/E ratios, AZN is more expensive than all of the above, except Moderna, which is really in a different category. AZN is also more expensive than all but Moderna and AbbVie in terms of price to book. Yet, AstraZeneca pays out a far lower dividend than all except Moderna (no dividend), in terms of yield. I am not interested in buying AZN even on this dip.

The Chart

With the exception of that mid-July spike, American Depository Shares of AZN have traded in a tight range since last April, peaking close to the $58 level a number of times, while bounding off of the $50 level on numerous occasions. 

On Monday morning, this stock will knock on that door once again. I would rather buy these shares on any momentum-based rally coming off of support should that support show up yet again, than risk buying the shares just above support. One of these times, that door is going to swing open.

If I were long the shares, the $50 level would be my panic point, not an add. At least not until it proves itself again. I am going to sit on my hands in this name today.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Guilfoyle was long PFE, MRNA, MRK, JNJ, ABBV equity.

TAGS: Mergers and Acquisitions | Investing | Markets | Stocks | Technical Analysis | Trading | U.S. Equity | Global Equity | Coronavirus

More from Stocks

When it Comes Time to Sell, Will You Act or Will You Freeze?

James "Rev Shark" DePorre
Jan 16, 2021 10:00 AM EST

Why don't more people embrace the ease and power of selling stocks? Why do they freeze and do nothing as losses build?

Hungry Traders and Stock Opportunities Aren't Likely to Go Away Soon

James "Rev Shark" DePorre
Jan 15, 2021 4:40 PM EST

It doesn't take much time for stocks with strong momentum to reset and continue on their way.

At What Price Is Ballard Power Systems a Buy?

Bruce Kamich
Jan 15, 2021 3:09 PM EST

Let's check out the latest charts of BLDP.

United Parcel Service Is Testing Key Support

Bruce Kamich
Jan 15, 2021 2:30 PM EST

A look at the charts of UPS.

A Buy and Hold Play With Hennessy Capital V

Timothy Collins
Jan 15, 2021 2:24 PM EST

HCICU hit the public markets today.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • 08:35 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/13/2021

    Lower highs... SPX (Long-Term View) The 1/8/2...
  • 08:07 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/12/2021

    Watch if the recent trend of lower highs continues...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login